Uveitis and Autoimmune Ocular Inflammation

Uveitis encompasses a spectrum of intraocular inflammatory disorders affecting the uveal tract (iris, ciliary body and choroid) and adjacent structures. Although often classified by anatomical location—anterior, intermediate, posterior and panuveitis—this group of conditions shares an underlying propensity for immune-mediated tissue damage. Autoimmune ocular inflammation arises when self-reactive lymphocytes, driven by genetic predisposition and environmental triggers, breach the immune privilege of the eye. Clinically, patients present with pain, photophobia, blurred vision and floaters; chronic inflammation may lead to cataract, glaucoma, macular oedema and irreversible vision loss. Advances in imaging, including ultra-wide-field angiography, have improved disease detection and monitoring. At the molecular level, dysregulation of T helper subsets, dysbalanced cytokine networks and impaired regulatory T-cell function underpin persistent inflammation. Management combines local and systemic corticosteroids with conventional immunosuppressants (for example methotrexate or cyclosporine) and, increasingly, targeted biologic agents. Despite progress, heterogeneous aetiologies and variable treatment responses pose ongoing challenges in tailoring therapy and preventing long-term sequelae.

Research from Nature Portfolio

Recent clinical trials have refined the therapeutic landscape for granulomatous autoimmune uveitis. A randomised non-inferiority study compared a cyclosporine-based immunosuppressant strategy with an adalimumab-based biologic approach, each combined with a modified corticosteroid regimen, in patients with Vogt–Koyanagi–Harada disease. By week 26, visual acuity gains in the cyclosporine group were statistically non-inferior to those achieved with adalimumab, and serious adverse events occurred less frequently. These findings support cyclosporine as a cost-effective alternative to biologics in selected patients and underscore the importance of phase-specific treatment stratification.

Uveitis and Autoimmune Ocular Inflammation publication trend

The graph below shows the total number of articles in uveitis and autoimmune ocular inflammation across all publications each year (not limited to Nature Index journals).

Technical terms

Uvea: The vascular middle layer of the eye comprising iris, ciliary body and choroid.

Anterior uveitis: Inflammation confined to the front of the eye, involving the iris and ciliary body.

Panuveitis: Inflammatory involvement of all uveal regions.

Vogt–Koyanagi–Harada disease: A granulomatous autoimmune syndrome targeting melanocyte-containing tissues, notably the choroid.

Biologic therapy: Treatment employing monoclonal antibodies or fusion proteins to inhibit specific immune mediators.

Immunosuppressant: A drug that dampens immune responses, often by inhibiting lymphocyte proliferation or function.

References

1. A de novo missense mutation in MPP2 confers an increased risk of Vogt–Koyanagi–Harada disease as shown by trio-based whole-exome sequencing. Cellular & Molecular Immunology (2023).
2. A randomized non-inferiority trial of therapeutic strategy with immunosuppressants versus biologics for Vogt-Koyanagi-Harada disease. Nature Communications (2023).
3. Autoimmune and autoinflammatory mechanisms in uveitis. Seminars in Immunopathology (2014).